WIPO Arbitration and Mediation Center



Sanofi-Aventis v. Shenzen Investments

Case No. D2007-0263


1. The Parties

The Complainant is Sanofi-Aventis, Gentilly, France, represented by Armfelt & Associés Selarl, France.

The Respondent is Shenzen Investments, Willemstad, Curacao, Netherlands.


2. The Domain Name and Registrar

The disputed domain name <rx4acomplia.com> is registered with eNom.


3. Procedural History

The Complaint was filed with the WIPO Arbitration and Mediation Center (the ”Center”) on February 22, 2007. On February 26, 2007, the Center transmitted by email to eNom a request for registrar verification in connection with the domain name(s) at issue. On February 26, 2007, eNom transmitted by email to the Center its verification response confirming that the Respondent is listed as the registrant and providing the contact details for the administrative and technical contact. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).

In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on March 1, 2007. In accordance with the Rules, paragraph 5(a), the due date for Response was March 21, 2007. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on March 26, 2007.

The Center appointed Richard Hill as the sole panelist in this matter on March 29, 2007. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.


4. Factual Background

The Complainant owns various registered and common law trademarks for the string ACOMPLIA.

The Complainant uses those marks to market a pharmaceutical product.

The Respondent is using the contested domain name to point to a website that offers various prescription pharmaceutical products, including the products marketed by the Complainant.

The Respondent does not have any licenses or other authorization from the Complainant to use the Complainant’s marks.


5. Parties’ Contentions

A. Complainant

The Complainant made the following allegations:

The Complainant is a very large and well-known multinational pharmaceutical company present in more than 100 countries across 5 continents.

The Complainant has filed trademark applications for ACOMPLIA in more than 100 countries and has obtained registered trademark rights in many countries. The Complainant also registered numerous domain names worldwide containing the ACOMPLIA trademark, for example <acomplia.com>, <acomplia.fr>, <acomplia.us>.

The Respondent’s registration consists of the Complainant’s trademark in addition with the descriptive word “RX4” and the gTLDs “.com”.

A wide variety of panelists have considered that the addition of generic and/or descriptive words to trademarks was not sufficient to escape the finding of similarity and does not change the overall impression of the designations as being connected to the Complainant (see Sanofi-Aventis v. Direct Response Marketing aka DRM, WIPO Case No. D2005-0661; Sanofi-aventis v. Elizabeth Riegel and Andrew Riegel, WIPO Case No. D2005-1045; Telstra Corporation Ltd v. Peter Lombardo, Marino Sussich and Ray Landers, WIPO, Case No. D2000-1511; Pepsico Inc v. Pepsi SRL and EMS COMPUTER INDUSTRY, WIPO Case No. D2003-0696; Pepsico Inc v. Diabetes Home care and DHC services, WIPO Case No. D2001-0174; Sony Kabushiki Kaisha v. Kil Inja, WIPO Case No. D2000-1409; America Online Inc v. Chris Hoffman, WIPO Case No. D2001-1184).

There is no license, consent or other right by which the Respondent would have been entitled to register or use the domain name with the Complainant’s trademark ACOMPLIA with the adjunction of the descriptive word “RX4”.

There is no doubt that the Respondent is aware that ACOMPLIA corresponds to a medical product and therefore to a trademark in respect of the content of its website.

Therefore, the Respondent’s use does not satisfy the test for bona fide use established in prior WIPO decisions.

The disputed domain name used by the Respondent, leads to an active website where information about the ACOMPLIA product is provided and where that product is offered for sale. Further, the website offers counterfeiting products or related placebo products.

Thus there can be no doubt that the Respondent knew the product, sold under the Complainant’s trademark ACOMPLIA, when it registered the disputed domain name.

By using its website under the disputed domain name to sell the Complainant’s products without any authorisation, the Respondent is intentionally attempting for a commercial purpose to attract Internet users to the Respondent’s website, and creates a likelihood of confusion with the Complainant’s trademark. This is in violation of the Policy.

Indeed, Paragraph 4(b)(iv) of the Policy lists as one of the typical situation as evidence of bad faith the fact of “ using the domain name, the Respondent has intentionally attempted to attract, for commercial gain, Internet users to its website, by creating a likelihood of confusion with the Complainant’s mark as to the source, sponsorship, affiliation, or endorsement of its website or of a product or service on its website”.

Moreover, any Internet user who will try to connect to this website will believe that the Respondent’s pharmaceutical product medicine is available in all countries without any medical control, whereas, (i) it has not been yet launched in all countries as this medicine has not been granted with all the administrative market authorization required, (ii) and can only be obtained by medical prescription.

Therefore, the use of the disputed domain name, by selling pharmaceuticals (including products other than the Complainant’s product) without requiring proof of a physical examination by an authorized doctor, is potentially harmful to the health of Internet users. And this also constitutes bad faith in the sense of the Policy.

B. Respondent

The Respondent did not reply to the Complainant’s contentions.


6. Discussion and Findings

A. Identical or Confusingly Similar

The contested domain name is obviously confusingly similar to the Complainant’s mark ACOMPLIA. The Panel notes the cases cited by the Complainant to support this point and agrees that those citations are appropriate.

B. Rights or Legitimate Interests

The Respondent does not have any license or other authorization to use the Complainant’s mark. The Respondent is using the disputed domain name to operate a website offering the sale of various pharmaceutical products, including the Complainant’s products.

The Panel finds that Respondent is redirecting Internet users interested in Complainant’s products and services to its own website for commercial gain and that such use does not fall within the parameters of a bona fide offering of goods or services pursuant to paragraph 4(c)(i) of the Policy or a legitimate noncommercial or fair use pursuant to paragraph 4(c)(iii) of the Policy. See The Royal Bank of Scot. Group v. Demand Domains, FA 714952 (Nat. Arb. Forum Aug. 2, 2006) (finding that the operation of a commercial web directory displaying various links to third-party websites was not a use in connection with a bona fide offering of goods or services pursuant to Policy paragraph 4(c)(i) or a legitimate noncommercial or fair use pursuant to Policy paragraph 4(c)(iii), as the respondent presumably earned “click-through” fees for each consumer it redirected to other websites); see also Persohn v. Lim, FA 874447 (Nat. Arb. Forum Feb. 19, 2007) (finding that the respondent was not using a disputed domain name in connection with a bona fide offering of goods or services or a legitimate noncommercial or fair use by redirecting Internet users to a commercial search engine website with links to multiple websites that may be of interest to the complainant’s customers and presumably earning “click-through fees” in the process).

Therefore, the Panel find that the Respondent does not have rights or legitimate interests in the domain name.

C. Registered and Used in Bad Faith

It is clear that the Respondent was aware of the Complainant’s marks when it registered and started using the disputed domain name, because its website refers to the Complainant’s products and features the Complainant’s mark.

The Respondent (who did not reply) has not presented any plausible explanation for its use of the Complainant’s mark. In accordance with Rules paragraph 14(b), the Panel shall draw such inferences from the Respondent’s failure to reply as it considers appropriate. Accordingly, the Panel finds that the Respondent did not have a legitimate use in mind when it registered the disputed domain name.

Indeed the Respondent’s actual use of the disputed domain name (as noted above) is clearly not bona fida, because the Respondent operates a website that sells the Complainant’s product (and other prescription medicine). This indicates that the Respondent has registered and is using the disputed domain name to take advantage of the confusing similarity between the disputed domain name and Complainant’s mark in order to profit from the goodwill associated with the mark in bad faith under paragraph 4(b)(iv) of the Policy. See Zee TV USA, Inc. v. Siddiqi, FA 721969 (Nat. Arb. Forum July 18, 2006) (finding that the respondent engaged in bad faith registration and use by using a domain name that was confusingly similar to the complainant’s mark to offer links to third-party websites that offered services similar to those offered by the complainant); see also The Ass’n of Junior Leagues Int’l Inc. v. This Domain Name My Be For Sale, FA 857581 (Nat. Arb. Forum Jan. 4, 2007) (holding that the respondent’s use of the disputed domain names to maintain pay-per-click sites displaying links unrelated to the complainant and to generate click-through revenue suggested bad faith registration and use under Policy paragraph 4(b)(iv)).


7. Decision

For all the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the domain name <rx4acomplia.com> be transferred to the Complainant.

Richard Hill
Sole Panelist

Dated: April 12, 2007